Comparative study reveals altered inflammatory mediator secretion linked to epithelial TSLP in COPD patients, indicating potential benefits of targeted anti-alarmin therapies.
Thymic stromal lymphopoietin (TSLP) is an alarmin cytokine activated by allergens, pathogens, and air pollutants. Recent studies suggest TSLP dysregulation in chronic inflammatory diseases. It was highlighted as a key player in the context of asthma-associated mucosal immunity. This study investigated the production and localization of TSLP and its receptors in airway epithelial cells and the related inflammatory response in chronic obstructive pulmonary disease (COPD) and non-COPD patients. TSLP transcripts and proteins were detected in epithelial cells but were not abundant at a steady state. The secretion of airway inflammatory mediators was altered in COPD in association with TSLP production. The cellular and molecular characterization of TSLP signaling may identify COPD patients that could benefit from anti-alarmin therapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Cherif et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: